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KinaseLow-to-moderate red wine consumption appeared to reduce age-related neurological disorders including
macular degeneration, stroke, and cognitive deﬁcits with or without dementia. Resveratrol has been considered
as one of the key ingredients responsible for the preventive action of red wine since the stilbene displays a
neuroprotective action in various models of toxicity. Besides its well documented free radical scavenging and
anti-inﬂammatory properties, resveratrol has been shown to increase the clearance of beta-amyloid, a key
feature of Alzheimer's disease, and to modulate intracellular effectors associated with oxidative stress
(e.g. heme oxygenase), neuronal energy homeostasis (e.g. AMP kinase), program cell death (i.e. AIF) and
longevity (i.e. sirtuins). This article summarizes the most recent ﬁndings on mechanisms of action involved in
the protective effects of this multi target polyphenol, and discusses its possible roles in the prevention of various
age-related neurological disorders. This article is part of a Special Issue entitled: Resveratrol: Challenges in
translating pre-clinical ﬁndings to improved patient outcomes.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
It is well known that a healthy diet may delay the occurrence of age-
related neurological disorders such as Alzheimer's and Parkinson's
diseases and stroke [1,2]. Hence, it has been reported that regular
consumption of fruits, vegetables and ﬁsh lowered the risk of cognitive
decline related or not to dementia in the elderly population [1]. More-
over, older adults who consume red wine (up to three glasses per
day) on a regular basis reduced (up to 50%) the risk of developingsease; AIF, Apoptosis Inducing
tor protein-1; BBB, blood-brain
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atrol: Challenges in translating
versity Institute, Perry Pavilion,dementia, such as Alzheimer's disease (AD) and vascular dementia, as
well as macular degeneration [1,3,4]. This is of particular interest since
the number of people that will be at-risk or affected by age-related
neurological disorders will rise, resulting in an increase in economic
burden of care and treatment of patients.
Scientists have intensively investigated themechanisms of action by
which protective diet, and particularly red wine, prevents age-related
neurodegenerative diseases. Although there are numerous polyphenols
present in red wine that may be responsible for its beneﬁcial effect,
resveratrol has drawn particular attention because it is considered as a
red wine-derived polyphenol with cardioprotective effects [5,6].
Numerous studies ranging from cell cultures to animal studies have
demonstrated that resveratrol exhibits anti-inﬂammatory and antioxi-
dant properties, inhibits beta-amyloid (Aβ) protein aggregation and
modulates intracellular effectors involved in neuronal cell survival/
death. More recently, resveratrol has been proposed to exert neuropro-
tective effects through activation of SIRT1, an enzyme that deacetylates
proteins associatedwith cellular regulation [7]. Here,we reviewpossible
mechanisms underlying the purported neuroprotective action of
resveratrol in vitro as well as rodent models of diseases. See Table 1
and Fig. 1 for details.
2. Reactive oxygen species
Higher levels of reactive oxygen species (ROS) in aging were
shown to be associated with cognitive deﬁcits related or not to AD
Table 1
Summary of the protective effects of resveratrol.
Effects Proposed underlying mechanisms References
Increases cerebral blood ﬂow (250 and 500 mg) during cognitive task
performance in health adults
Vasodilatory activities [97]
Protects and rescues (5–25 μM) hippocampal neuronal cells against toxicity
induced by nitric oxide
Free radical and ion metal scavenging activities [11]
Protects (25 μM) primary neuronal cells against excitotoxicity Increase in HO 1 protein levels [16]
Protects (10–60 μM) mitochondria against oxidative stress Phosphorylation of GSK3β [19]
Protects (10–40 mg/kg/day for 10 weeks) dopaminergic neuronal cells
exposed to 6-hydroxydopamine (6-OHDA)
Reduction of the expression of COX-2 protein and tumor necrosis factor α
(TNFα) in the substantia nigra
[21]
Inhibits (up to 50 μM) the activation of microglia exposed to
lipopolysaccharide (LPS)
Reduction of the production/expression of prostaglandins, NO, TNFα, COX-1
and NF-κB
[23–26]
Protects (15–60 μM) against LPS-induced dopaminergic neuronal death Attenuation of the activation of MAPK and NF-κB in microglia [27]
Protects (15–40 μM) hippocampal cells exposed to Aβ peptides – Induction of the phosphorylation of PKCδ isoform.
– Inhibition and destabilization of Aβ1–42 ﬁbril formation
[38,42,51]
Protects (10–20 μM) HT22 hippocampal cells against Aβ-induced toxicity Inhibition of the Aβ1–42-induced activation of GSK3β and AMPK activity [41]
Reduces (diet supplemented with 3.5 g/l of resveratrol for 2 weeks) in
brain Aβ levels and amyloid deposition in mice
– Activation of the degradation of Aβ via a mechanism that involves
proteasome
– Activation of the AMPK signaling pathway
[56]
Reduces (75 and 100 μM) neuronal death in CA1 region of the hippocampus
exposed to ischemia
Activation of SIRT1 [62]
Protects (7.5 μM) neuroblastoma cell line exposed to 6-OHDA Activation of SIRT1 [60]
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ability to scavenge free radicals and metals (i.e. copper) and to up-
regulate endogenous antioxidant enzymes including glutathione
peroxidase [9,10]. We have shown that resveratrol is able to protect
and even rescue hippocampal neurons that were exposed to nitric
oxide (NO), an effect that could be explained, at least in part, by its
purported antioxidant activities, as well as its ROS scavenging proper-
ties [11].
Resveratrol may also play a beneﬁcial role in the cellular response
by modulating enzymes involved in stress response, such as quinone
reductase 2 (QR2), a cytosolic enzyme which enhances the production
of damaging activated quinone and ROS [12]. Our group demonstrated
that QR2 is overexpressed in the hippocampus – a brain area involved
in learning and memory and severally affected in AD – in rat models
of learning deﬁcits, suggesting that the overexpression of this enzyme
triggers memory impairments [13]. This hypothesis is supported by
the fact that selective inhibitors of QR2 were able to block hippocampal
neuronal cell death induced by menadione, a QR2 substrate [13].
Interestingly, resveratrol inhibits QR2 at low micromolar concentration
(IC50 of 2.9 μM) [14], an effect that may lead to an increase in
cellular resistance against oxidative stress-induced neuronal death
[15]. Besides its inhibitory action on QR2, resveratrol has been
shown to induce heme oxygenase 1 (HO1), an endogenous enzyme
that provides resistance against oxidative stress-related neuronal
damage [16]. The authors ﬁrst showed that resveratrol (25 μM)
increased HO1 protein levels in primary neuronal cells exposed to
glutamate, an effect that was due to an increase in HO1 protein
synthesis. Moreover, a pre-treatment with resveratrol (20 mg/kg)
signiﬁcantly attenuated infarct size in wild-type but not HO1
knockout mice exposed to ischemia, suggesting that the polyphenol
also interacts in vivo with the enzyme [16]. Using neuronal cell lines,
Dasgupta andMilbrandt [17] showed that resveratrol is a potent activa-
tor of AMP-activated protein kinase (AMPK), a key regulator of cell sur-
vival in response to oxidative stress insults [18]. Moreover, resveratrol
was shown to protect mitochondria against oxidative stress induced
by a mixture of arachidonic acid and iron, through a mechanism that
involves AMPK-dependent phosphorylation of glycogen synthase
kinase-3beta (GSK3β) [19]. These authors also reported that the neuro-
protective action of resveratrol depends on the presence of liver
kinase B1 (LKB1), an upstream kinase of AMPK [19]. Furthermore,
this LKB1-dependent mitochondrial protection resulted from
resveratrol's poly(ADP-ribose)polymerase activation, but not SIRT1 ac-
tivation [19].3. Neuroinﬂammation
Microglial activation may contribute to neuronal death during brain
damage by releasing neurotoxic pro-inﬂammatory molecules [20].
It has been reported that resveratrol inhibits the pro-inﬂammatory
molecules known as cyclooxygenases, particularly cyclooxygenase-1
(COX1) (for review see [10]), an enzyme involved in the production of
pro-inﬂammatory molecules known as cytokines. Moreover, Jin et al.
[21] showed that resveratrol exerted an in vivo neuroprotective action
against toxicity induced by 6-hydroxydopamine (6-OHDA), and this ef-
fect was associated with its ability to reduce expression of COX-2 and
tumor necrosis factor α (TNFα) in the substantia nigra. Resveratrol is
also able to reduce the release of pro-inﬂammatory factors through
the inhibition of cellular cascade signaling pathways involving nuclear
factor-kappaB (NF-κB) and activator protein-1 (AP-1) [22]. Using rat pri-
mary microglia cultures exposed to lipopolysaccharide (LPS), it has been
reported that resveratrol (up to 50 μM) reduced the production of pros-
taglandins (e.g. PGE2), NO, and TNFα, as well as the expression of COX-1
and activation of NF-κB [23–26]. Finally, it has been shown that resvera-
trol (15–60 μM) protected against dopaminergic neuronal death induced
by LPS by attenuating the activation ofmitogen-activated protein kinases
(MAPKs) and NF-κB signaling pathways, supporting the hypothesis that
neuroprotection triggered by resveratrol involved inhibition of
microglia-mediated neuroinﬂammation [27].
Astrocytes, a type of glial cells, actively regulate brain energymetab-
olism, neurotransmitter release, ionic homeostasis and defense against
oxidative stress [28,29]. Using a model of astrocytes exposed to H2O2,
Quincozes-Santos et al. [30] have reported that resveratrol (100 μM)
decreased nitrite and nitrogen species levels, whose overproduction
likely plays a role in Alzheimer's and Parkinson's diseases [31]. More-
over, resveratrol enhanced per se HO1 expression and reduced ROSpro-
duction possibly through its HO1 in these cells [30]. HO1 can also reduce
NF-κB activation (for review, see [32]). Finally, it has been recently
shown by the same group that resveratrol stimulated antioxidant
defenses by increasing glutathione levels and decreased cytokines in
rat hippocampal cultured astrocytes [33], a process that may explain
its protective action against toxicity associatedwith neuroinﬂammation
and be relevant to neurodegenerative diseases [34].
4. Amyloidogenesis
There is accumulative evidence suggesting that progressive accumu-
lation of Aβ plaques plays a crucial role in neuronal death occurring in
Fig. 1. Summary of the neuroprotective action of resveratrol. Resveratrol displays potent antioxidant activity by scavenging free radicals and metals, protecting against NO toxicity,
reducing QR2 activity and upregulating endogenous enzymes such as glutathione peroxidase, HO-1, AMPK and LKB1. The polyphenol also inhibits pro-inﬂammatory enzyme
(i.e. COX-1 and -2) expression, reduces NF-κB activation as well as PGE2, NO, and TNFα production, cytokine release and increases HO1 expression and activity in astrocytes. It protects
against Aβ-induced toxicity by reducing GSK-3β activity and may promote Aβ clearance. Treatment with resveratrol can affect multiple signaling pathway effectors involved in cell
survival (AMPK, PI3-k, AkT), programmed cell death (caspase-3/12, Bax, MMP-3/9, AIF, cytochrome c) and synaptic plasticity (PKC, ERK1/2). Direct and/or indirect activation of the
deacetylase sirtuins by resveratrol has also been suggested.
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accumulation may be an effective therapeutic approach to block neuro-
nal damage in AD [36,37]. Our group reported that Aβ peptide-induced
hippocampal neuronal death was dose-dependently reduced in the
presence of resveratrol (15–40 μM) [38,39]. Similar protective action
was obtained with resveratrol and other derivatives (e.g. piceatannol)
in PC12 cells [40] and murine HT22 hippocampal cell line [41]. Kwon
et al. [41] reported that resveratrol inhibited both the Aβ1–42-inducedactivation of GSK3β and AMPK activity. Other mechanisms have also
been proposed to explain the neuroprotective action of resveratrol in
Aβ-related neurotoxicity. For example, resveratrol and its derivatives
were shown to directly interact with Aβ peptides by inhibiting and
destabilizing the formation of Aβ1–42 ﬁbrils [42]. However, Granzotto
and Zatta [43] reported that resveratrol was unable to prevent Aβ ﬁbril
formation in human neuroblastoma cells exposed to Aβ suggesting that
resveratrol acts not through anti-aggregative pathways but mainly via
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display anti-amyloidogenic effect by promoting Aβ clearance, rather
than inhibiting its production [44,45]. Indeed, using HEK293 and N2a
cells transfected with human amyloid precursor protein (APP) 695,
Marambaud et al. [44] have shown that resveratrol (0–40 μM)attenuated
the levels of intracellular- and extracellular-secreted Aβ clearance but
had no effect on the production of α, β, or γ-secretases. However,
Jeon et al. [46] demonstrated that resveratrol displayed inhibitory
activities of β-secretase with an IC50 of 15 μM. Moreover, resveratrol
did not affect Aβ degradation by interacting with the enzymes known
as metalloendopeptidase-neprilysin, endothelin-converting enzyme-1
and -2, and insulin-degrading enzyme. However, it affected proteasome
through a mechanism that does not increase the total activity of the
proteasome [44], which is one of the main cellular mechanisms that
enzymatically degrade misprocessed and misfolded proteins [47].
It has been suggested that the accumulation of soluble forms of Aβ
oligomers (known as Aβ-derived diffusible neurotoxic ligands or
ADDLs), that are present in the brain and cerebrospinal ﬂuid of AD
patients [48,49], contributes to neurodegeneration occurring in AD
[50]. Resveratrol has been reported to directly bind to Aβ1–42, interfere
in Aβ1–42 aggregation, change the Aβ1–42 oligomer conformation and at-
tenuate Aβ1–42 oligomeric cytotoxicity [51], whereas another group
suggested that it remodels three of Aβ conformers (i.e. soluble oligo-
mers, ﬁbrillar intermediates, and amyloid ﬁbrils) into aggregated
forms that are non-toxic [52].
The activation of protein kinase C (PKC) may stimulate α-secretase
and then non-amyloidogenic pathway in APP processing, resulting in
a reduction in the production of Aβ [53]. Our group reported that
dihydrochloride3-(1-[3-(dimethylamino) propyl]-1H-indol-3yl)-4-
(1H-indol-3-yl)-1H-pyrrole-2,5-dione (GF 109203X), a PKC inhibitor,
attenuated the neuroprotective effects of resveratrol against Aβ-
induced toxicity in hippocampal cell cultures [38]. Moreover, Western
blot data suggested that resveratrol (20–30 μM) induced the phosphor-
ylation of the PKC delta (δ) isoform, whose inhibition is required for
initiation of the apoptotic pathway [54]. Taken together, these results
support the idea that resveratrol protect neuronal cells against Aβ-
induced toxicity through a mechanism that involves a stimulation
of PKC isoforms (particularly the δ isoform), possibly leading to an inac-
tivation of GSK3β. In support of this hypothesis, phorbol 12-myristate
13-acetate, a PKC activator, has been shown to block primary hippo-
campal neuronal cell death exposed to Aβ and to inhibit GSK3β via a
mechanism that involves serine 9 phosphorylation [55]. Finally,
Vingtdeux et al. [56] studied whether AMPK – a metabolic effector
that promotes neuronal survival following glucose deprivation [57] –
is involved in the ability of resveratrol to lower Aβ levels and plaques.
Using cultured cells, they showed that resveratrol activated AMPK by
increasing intracellular calcium levels and that the inhibition of AMPK
counteracted the effect of resveratrol on Aβ levels. This effect was also
obtained in vivo since a peripheral administration of resveratrol activated
AMPK and reduced cerebral Aβ levels and accumulation in the mouse
cerebral cortex, likely via an SIRT-independent pathway [56].
5. Sirtuins
It has been reported that activation of sirtuins, particularly SIRT-1,
may protect neurons against apoptosis, inﬂammation and oxidative
stress, suggesting that these enzymes might be new targets for the
treatment of neurological disorders such as stroke, AD and Parkinson's
disease (PD) [58]. Various groups showed that resveratrol is a SIRT1 ac-
tivator [59–61]. Some evidence suggests that the neuroprotective action
of resveratrol in models of ischemia or PD involves SIRT1. For example,
Raval et al. [62] demonstrated that resveratrol can mimic ischemic pre-
conditioning, an event that protects against subsequent ischemic insults.
The inhibition of SIRT1 during reperfusion blocked the neuroprotective
effect of resveratrol treatment in the hippocampus, suggesting a SIRT-
dependent protective action of resveratrol. In another study, it wasobserved that activation of SIRT-1 induced by resveratrol strongly
reduced the NF-κB signaling pathway in glial cells exposed to Aβ-
induced toxicity [63]. Moreover, a down-regulation of SIRT1 expression
abolished the protective action of resveratrol in neuroblastoma cell line
exposed to 6-OHDA [60]. More recently, Zhang et al. [64] investigated
the role of SIRT1 in the neuroprotective action of resveratrol against
Aβ25–35 neurotoxicity. Results showed that a treatmentwith Aβ25–35 re-
duced SIRT1 expression that was restored by resveratrol. Nicotinamide,
a SIRT1 inhibitor, attenuated the protective action of resveratrol against
Aβ25–35-induced toxicity. Moreover, the decrease in phosphorylation of
Akt1 was associated with a down-expression of SIRT1, an effect that
was reversed by resveratrol. Taken together, these ﬁndings suggest
that the polyphenol activates SIRT1 which in turn enhances activity of
Akt, resulting in cell protection [64]. Although resveratrol has been
widely referred to as a SIRT1 activator [59,60], its ability to directly acti-
vate SIRT1 remains questionable. Recently, two groups reported that
resveratrol may only indirectly increase SIRT1 activity by promoting
nicotinamide adenine dinucleotide (NAD) levels induced by AMPK acti-
vation [65,66]. Moreover, resveratrol has been shown to display meta-
bolic beneﬁts by inhibiting cAMP phosphodiesterases in myoblast
cells, leading to activation of AMPK and SIRT1 [67]. Treatment with res-
veratrol can improve health and survival of mice on a high-calorie diet
by inducing changes associatedwith longer lifespan including increased
AMPK activity [68]. Theseﬁndings suggest that resveratrol indirectly ac-
tivates SIRT1 and may be viewed as a calorie restriction mimetic with
potential neuroprotective action [67,68]. Further studies are undoubt-
edly required to fully establish the relationship between mechanisms
involved in the neuroprotective action of resveratrol and the sirtuins.
6. PI3/Akt kinases
The putative role of the phosphoinositide3-kinase (PI3-k) pathway
and MAPK in the action of resveratrol was investigated in an in vitro
model of ischemia [69]. The neuroprotective action of resveratrol
(50 μM) in organotypic hippocampal cultures exposed to oxygen–
glucose deprivation (OGD) was shown to be prevented by LY294002,
an inhibitor of PI3-k, but not by PD98059, a blocker ofMAPK [69]. More-
over, they showed that resveratrol induced the activation of Akt
and extracellular signal-regulated kinase-1 and -2 (ERK1/2) and the
phosphorylation/inactivation of GSK3β, suggesting that the PI3-k/Akt
pathway mediates the neuroprotective effect of resveratrol. Similar
results were also obtained in cardiomyocytes [70].
7. Protein kinase C
Our group has shown that PKC enzymes are involved in the neuro-
protective effect of resveratrol against Aβ-induced neurotoxicity [38,
71]. Recently, our group has reported that the activity of the gamma
(γ) isoform is linked to successful cognitive aging [72], while another
group found that protein levels of PKCγ are lower in an AD mouse
model [73]. It has therefore been postulated that the purported
cognitive enhancing properties of polyphenols in memory-impaired
animals [74] could be due to their stimulatory effects on PKCγ activity.
Accordingly, we investigated the effects of resveratrol on PKCγ activa-
tion in hippocampal neuronal cells exposed to GF 109203X, an inhibitor
of PKC. Resveratrol prevents GF 109203X-induced neuronal death and
the disruption of cytoskeleton organization [75]. Interestingly, resvera-
trol increased both phosphorylation and expression of PKCγ, suggesting
an active role for this enzyme in neuronal cell survival promoted by this
polyphenol [75]. PKC signaling is involved in the regulation of multiple
signaling pathways [76,77]. Future studies with novel tools such as
genetically-encoded reporters, peptides derived from receptors for acti-
vated C kinase or kinase-deadmutants (for review, see [78]) will be re-
quired to evaluate the speciﬁc effect of resveratrol on PKC enzymes,
notably PKCγ.
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It has been suggested that Aβ-induced neuronal death is related
to different programmed cell death (PCD) pathways; a caspase-
dependent apoptotic PCD [79] and an Apoptosis Inducing Factor (AIF)-
mediated, caspase-independent PCD [80]. Polyphenols may also
modulate caspase-dependent and -independent programmed PCD
pathways [81]. In rat cultured cortical neurons, resveratrol (0.1–
10 μM) reduces apoptotic events generated by OGD/reperfusion such
increased expression of caspase-3 and -12 in neurons and the inhibition
of the calcium overload [82]. More recently, it has been shown that
resveratrol (50 μM) reversed apoptosis induced by OGD in primary
cultured cortical neuronal cells, and this effect was accompanied by a
decrease in the expression of Bax and the activation of caspase-3, as
well as an inhibition of matrix metalloproteinase (MMP)-9 and -3, via
a reduced activation of ERK1/2 and NF-κB pathway [83,84]. Studies
investigating the role of AIF, caspase-independent PCD in the neuropro-
tective action of resveratrol are rather sparse. It has been reported that
polyphenols including resveratrol can block in vitro glutamate and
1-methyl-4-phenylpyridinium ion (MPP+)-induced neuronal death
through inhibitory action on mitochondrial AIF release [85,86]. The
inhibitory action of resveratrol on AIF mitochondrial release is in
agreement with previous studies of Martinoli's group showing that
resveratrol (0.1 μM) reduced apoptotic events in dopamine-producing
PC12 cells exposed to either LPS-activated microglia [87] or 1-methyl-
4-phenylpyridinium ion (MPP+), a parkinsonian toxin [86]. In the
latest study, Bournival et al. [86] suggest that the anti-apoptotic action
of resveratrol may be due to its capacity to inhibit cytochrome c release
and the signiﬁcant rise of AIF (57 kDa form) in the cytosol and nucleus
produced by MPP+.
9. Bioavailability and clinical efﬁcacy of resveratrol
Resveratrol – and the preferred form trans-resveratrol – has been
identiﬁed from a number of dietary sources including red grapes,
berries (e.g. cranberries, bilberries, blueberries) and peanuts [5]. It
is also present in red wine and to a much lesser extent in white
wine. The concentration of trans-resveratrol in red wine depends on
the type of red wine and its geographic origin, ranging from 0.1 to
14.3 mg/l (i.e. 0.4–57 μM) [5]. The concentrations of resveratrol (up to
50 μM)present in redwine [88,89] aremuch higher than those required
to produce its purported in vitro protective action. Hence, only trace
amounts of free resveratrol (approximately 7 μg/l i.e. 30 nM) could be
detected in plasma 30 min after a 25 mg oral dose whereas the total
(free and conjugated) estimated resveratrol quantity was much higher
(around 450 μg/l, 2 μM) [90]. Although resveratrol has a poor bioavail-
ability and oral administration of resveratrol undergoes an extensive
metabolism in the intestine and liver [91], several animal studies have
shown that it is able to cross the blood–brain barrier (BBB). For example,
a chronic administration of resveratrol (8–30 mg/kg, intraperitoneal
(i.p.) injections) signiﬁcantly protected the hippocampus of rodents ex-
posed to either kainic acid [92] or to an occlusion of carotid arteries [93].
In the latest study, the authors found that signiﬁcant levels of resvera-
trol were detected in the brain after i.p. injection, reaching its peak at
4 h post-injection, supporting the hypothesis that it can cross the BBB,
at least in rodents [93]. Sinha et al. [94] reported that a peripheral treat-
ment with trans-resveratrol (20 mg/kg for 21 days) decreased the
volume of infarcts in rats subjected to focal ischemia. Finally, similar
in vivo protective action of resveratrol (5–300 mg/kg) was observed in
transgenic models of AD [61,95]. In the latest study, injections of lipid-
core nanocapsules containing resveratrol (5 mg/kg, i.p. injections)
were able to rescue the deleterious effects of Aβ1–42 while treatment
with resveratrol presented only partial beneﬁcial effect [95]. According
to the authors, these ﬁndings suggest that lipid-core nanocapsules
strongly increased resveratrol concentration in the brain tissue [95].
It is therefore unlikely that resveratrol is the sole polyphenol thatmay explain the purported beneﬁcial effects of red wine in the
elderly population [3,96] since resveratrol intake of 25 mg corresponds
to the consumption of more than 4 l of red wine. A few studies
have been performed to assess the effects of oral resveratrol on
cognitive performance in both healthy and cognitively impaired
patients. Based on the vasodilatory action of resveratrol, Kennedy et al.
[97] aimed to investigate whether the polyphenol improves blood ﬂow,
which thereby promotes cognitive function. In a randomized, double-
blind, placebo-controlled study involving 22 healthy adults, they showed
that administration of resveratrol (250 and 500 mg) resulted in dose-
dependent increases in cerebral blood ﬂow during cognitive task
performance that activates the frontal cortex. However, cognitive
functions were not affected. The presence of free resveratrol was
conﬁrmed by high performance liquid chromatography,with concentra-
tions, peaking at 5.65 and 14.4 μg/l after 250 and 500 mg, respectively,
90 min after dosing [97]. In contrast, the glucuronidated and sulfated
conjugates were present in much higher concentrations 45 min after
the start of the cognitive tasks. Concentrations, particularly of the
sulfated conjugate, continued to rise to reach about 300 and 700 μg/l
for 250 and 500 mg of resveratrol, respectively, at the 90 min postdose
time point that corresponded to the end of the cognitive tasks [97]. The
same group reported more recently that a combination of piperine and
resveratrol (250 mg) signiﬁcantly augmented cerebral blood ﬂow dur-
ing task performance in the samepopulation, as comparedwith placebo
and resveratrol alone. However, cognitive function, mood and
blood pressure were not affected whereas the plasma concentrations
of resveratrol and its metabolites were not signiﬁcantly different
between the treatments [98]. Moreover, acute administration of
resveratrol has been reported to increase both endothelium-
dependent vasodilation and ﬂow-mediated dilation of the brachial
artery, an effect that may contribute to enhance cerebrovascular
and cognitive functions [99]. Currently, a clinical study is under way
to evaluate resveratrol as a dietary ingredient with beneﬁcial effects
in mild tomoderate AD. A phase 1, randomized placebo controlled
pilot study is under way to determine whether resveratrol (250–
1000 mg/day; for 12 to 52 weeks) supplementation is safe and improves
memory and physical performance in older adults (ClinicalTrials.gov
Identiﬁer: NCT01126229).
10. Conclusion
Resveratrol displayed pleiotropic activities including antioxidant and
anti-inﬂammatory effects, as well as an inhibitory action, supporting
that it is one of the most promising compounds for the development
of AD therapies (see Table 1). Several intracellular targets of resveratrol
have also been identiﬁed. However, the poor absorption of resveratrol
makes the development of analogs very challenging. The drug company
Sirtris Pharmaceuticals developed a formulation of resveratrol called
SRT501, with about ﬁve times higher bioavailability than resveratrol
itself. However SRT501 induced multiple side effects that caused the
termination of the clinical trial in patients withmultiple myeloma treat-
ed. More recently, resveratrol analogs such as pterostilbene have been
synthesized and have shown to be effective in rodent models of neuro-
toxicity [100]. Moreover, different strategies such as the use of nano-
technologies have been shown to improve the solubility and stability
of polyphenols, at least in rodents. Hence various methods such as the
use of lipid-core nanocapsules containing resveratrol have been shown
to improve the efﬁcacy of resveratrol. These new technologies should
be used to conﬁrm if resveratrol is a potential therapeutic agent in
age-related neurodegenerative disorders.
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